Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial.

Daniel, Rooks,; Therese, Swan,; Budhaditya, Goswami,; Lee Anne, Filosa,; Ola, Bunte,; Nicolas, Panchaud,; Laura A, Coleman,; Ram R, Miller,; Garayoa, Elisa, Garcia; Jens, Praestgaard,; Robert G, Perry,; Chris, Recknor,; Charles M, Fogarty,; Hidenori, Arai,; Liang-Kung, Chen,; Jun, Hashimoto,; Yoon-Sok, Chung,; John, Vissing,; Didier, Laurent,; Olivier, Petricoul,; Sarah, Hemsley,; Estelle, Lach-Trifilieff,; Dimitris A, Papanicolaou,; Ronenn, Roubenoff,

doi:10.1001/jamanetworkopen.2020.20836

Public

Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial.

Published in JAMA network open • Oct 1, 2020

Authors:

Rooks, Daniel

Swan, Therese

Goswami, Budhaditya

Abstract

IMPORTANCE: The potential benefit of novel skeletal muscle anabolic agents to improve physical function in people with sarcopenia and other muscle wasting diseases is unknown. OBJECTIVE: To confirm the safety and efficacy of bimagrumab plus the new standard of care on skeletal muscle mass, strength,...

Subject

Accidental Falls

Aged

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!